CAD GEN

CSI

EDU

CLINICAL CARDIOLOGY

Accredited Symposium

Accredited Symposium

THE GREAT DEBATE: ASPIRIN, DAPT OR DPI FOR SECONDARY PREVENTION IN STABLE ASCVD PATIENTS?

Co-Chair(s)

• 

  Shamir Mehta

  Interventional Cardiologist
  McMaster Unviersity
• 

  Jacob Udell, MD MPH FRCPC

  Cardiologist
  University of Toronto; Cardiovascular Division, Women's College Hospital and Peter Munk Cardiac Centre, University Health Network
  University of Toronto

Planning Committee Member(s)

• 

  Eva Lonn, MD, MSc, FRCPC, FACC

  Professor of Medicine and Population Health Research Senior Scientist, McMaster University
  McMaster University and Hamilton Health Sciences
  McMaster University
• 

  Jean-Francois Tanguay, MD, FRCPC, FACC, FAHA, FESC

  Director, Coronary Care Unit, Montreal Heart Institute
• 

  Robert Welsh, MD, FRCPC, FESC, FACC, FAHA

  Zone Clinical Department Head, Clinical Sciences and Interventional Cardiologist
  Mazankowski Alberta Heart Institute
  University of Alberta
• 

  Graham Wong, MD MPH

  Clinical Professor and Program Director, UBC Cardiology Training Program
  UBC
  CANCARE

This event is an accredited Group Learning Activity under Section 1 as defined by the Royal College of Physicians & Surgeons of Canada for the Maintenance of Certification program and has been approved by the Canadian Cardiovascular Society. This program was co-developed with the Canadian Cardiovascular Society and Bayer Inc. and was planned to achieve scientific integrity, objectivity and balance. This program was made possible through an educational grant from Bayer Inc.

Click here to view the program!

Learning Objectives

At the conclusion of this session, participants will be able to:

• recognize the risk of recurrent events in patients with atherosclerotic cardiovascular disease using case-based scenarios;
• assess the appropriateness of long-term antithrombotic regimen options for different patient types by reviewing the most recent evidence available; and
• determine which patients should be transitioned from DAPT to the COMPASS regimen.

Presentations:

• 12:30 PM - 12:35 PM

  WELCOME AND INTRODUCTIONS
  Shamir Mehta
• 12:35 PM - 12:40 PM

  IT'S TIME TO OVERCOME INERTIA IN "STABLE" ATHEROSCLEROTIC CV DISEASE
  Eva Lonn, MD, MSc, FRCPC, FACC – McMaster University and Hamilton Health Sciences
• 12:40 PM - 12:50 PM

  DEBATE: BE IT RESOLVED, IN STABLE ASCVD PATIENTS, IS ASPIRIN ENOUGH?
  Jacob A. Udell, MD MPH FRCPC – University of Toronto; Cardiovascular Division, Women's College Hospital and Peter Munk Cardiac Centre, University Health Network; Robert C. Welsh, MD, FRCPC, FESC, FACC, FAHA – Mazankowski Alberta Heart Institute
• 12:50 PM - 12:55 PM

  CASE STUDY: CHRONIC CAD
  Graham Wong, MD MPH – UBC
• 12:55 PM - 1:08 PM

  INTERACTIVE PANEL DISCUSSION AND LIVE AUDIENCE Q&A
  Shamir Mehta
• 1:08 PM - 1:13 PM

  CASE STUDY: POST-ACS WITH STENT
  Jean-Francois Tanguay, MD, FRCPC, FACC, FAHA, FESC
• 1:13 PM - 1:25 PM

  INTERACTIVE PANEL DISCUSSION AND LIVE AUDIENCE Q&A (VIA PARTICIPANT’S MOBILES)
  Shamir Mehta
• 1:25 PM - 1:30 PM

  CLOSING REMARKS
  Shamir Mehta